Stocks · News reference
Humacyte Q2 EPS $(0.16) Misses $(0.10) Estimate, Sales $406.000K Miss $1.116M Estimate
Humacyte (NASDAQ:HUMA) reported quarterly losses of $(0.16) per share which missed the analyst consensus estimate of $(0.10) by 60 percent. This is a 33.33 percent increase over losses of $(0.24) per share from the same
Reference details
Connected markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Aug 12, 2026, 11:01 AM
- Checked
- Aug 12, 2026, 11:01 AM
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related headlines
Humacyte shares are trading higher after the company announced the publication of one-year Phase 3 results of its acellular tissue engineered vessel for hemodialysis access in The Lancet Digital Health.
Read original at benzingaHumacyte Announces Publication Of One-Year V007 Phase 3 Results In The Lancet Digital Health Showing ATEV Superiority Over Autogenous Fistula For Hemodialysis Access
Read original at benzingaHumacyte Announces Symvess Acellular Tissue Engineered Vessel-Tyod Now Being Used By Arizona Surgeons
Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology company that develops bioengineered human tissues, today announced that Symvess, acellular tissue engineered vessel-tyod, is now being used by surgeons in
Read original at benzinga